Bertilimumab (Cambridge Antibody Technology Group)

Ding, C and Li, J and Zhang, X (2004) Bertilimumab (Cambridge Antibody Technology Group). Current Opinion in Investigational Drugs, 5 (11). pp. 1213-1219. ISSN 1472-4472

PDF - Full text restricted - Requires a PDF viewer
60Kb

Official URL: http://www.biomedcentral.com/1472-4472/5?issue=11

Abstract

Cambridge Antibody Technology (CAT) is developing bertilimumab, an anti-eotaxin-1 monoclonal antibody, for the potential treatment of allergic disorders. By September 2003, CAT had released results from phase I/II trials, and was seeking to outlicense rights for bertilimumab.

Item Type:	Article
ID Code:	3608
Deposited By:	Dr Changhai / C Ding
Deposited On:	01 Apr 2008 14:00
Last Modified:	18 Jul 2008 20:43
ePrint Statistics:	View statistics for this ePrint

Repository Staff Only: item control page